Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's semaglutide drugs for diabetes and obesity at a congressional hearin
The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the p
The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstru
A pharmacy benefit manager has thrown a legal punch at the Federal Trade Commission (FTC), taking issue with the agency's recent report accusing PBMs of using anti-competitive practices to
Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.